Corporate Social Responsibility Report

The report highlights Shanghai Pharmaceuticals' 2020 operating income of RMB191.909 billion and continued investment in pharmaceutical R&D, including development of innovative medicines and biomedical platforms. It records the establishment of a wholly controlled rare-disease business platform and details the Group's role in supplying medicines and medical materials during the COVID-19 response. The report also discloses annual group energy consumption of 118,000 tonnes of standard coal.